Neovasc Reducer™ Featured In Germany’s Second Largest National Newspaper
July 24 2020 - 9:50AM
via NEWMEDIAWIRE --
Neovasc, Inc. (“Neovasc” or
the “Company”) (NASDAQ, TSX: NVCN) announced today that the Neovasc
Reducer™ (the “Reducer”) was featured in a supplement titled:
“Volkskrankheiten” or “Common Diseases” in Frankfurter
Allgemeine Zeitung(FAZ), the second largest national newspaper by
circulation in Germany. The supplement will be mailed to
subscribers, reaching an estimated audience of almost 500,000 and
should be available in the waiting areas of physician offices
across Germany over the coming months.
A portion of the 20-page supplement is dedicated
to educating readers on Angina Pectoris, a common form of
debilitating chronic chest pain. In the first part of the article,
Dr. Sebastian Philipp from the Elbe Clinics in Stade, and Professor
Ulrich Schäfer from the Marienkrankenhaus in Hamburg, explain how
the Reducer, which has been available in Germany for four years,
provides a complementary therapy that should be used
when patients have exhausted anti-anginal therapy yet are still
symptomatic. Prof. Schäfer explains how the Reducer, once in place,
can take between six to eight weeks to improve blood
flow. As the patient improves, Prof. Schäfer recommends
patients consider taking up or continuing sporting activities such
as biking, running, hiking and swimming at a lower intensity to
improve their health.
Prof. Dr. Tommaso Gori, who leads the cardiac
catheterization lab at the prestigious University Hospital Mainz,
is featured in the supplement explaining how the Reducer therapy
can help patients with Chronic Angina Pectoris. Professor Gori
commented on the available robust clinical evidence on the safety
and efficacy of Reducer therapy and highlighted that, according to
the best research to date, 75% of patients treated with Reducer
feel better and experience less chest pain.
Fred Colen, President and Chief Executive Officer
of Neovasc, stated, “We are pleased that three prominent leaders in
heart disease have indicated that the use of Reducer is a welcomed
alternative for patients who are suffering from refractory angina,
a severely debilitating condition that affects millions
worldwide. The Reducer has been included as a treatment
option for refractory angina by the European Society of Cardiology
Practice Guidelines, and we believe the special supplement
in Frankfurter Allgemeine Zeitungwill help educate many in
Germany on how the Reducer can offer a solution for those suffering
from angina.”
About Neovasc Inc.
Neovasc is a specialty medical device company
that develops, manufactures and markets products for the rapidly
growing cardiovascular marketplace. The Company is a leader in the
development of minimally invasive transcatheter mitral valve
replacement technologies, and minimally invasive devices for the
treatment of refractory angina. Its products include the Neovasc
Reducer™, for the treatment of refractory angina, which is not
currently commercially available in the United States (2 U.S.
patients have been treated under Compassionate Use) and has been
commercially available in Europe since 2015, and Tiara™, for the
transcatheter treatment of mitral valve disease, which is currently
under clinical investigation in the United States, Canada, Israel
and Europe. For more information, visit: www.neovasc.com.
Forward-Looking Statement Disclaimer
Certain statements in this news release contain
forward-looking statements within the meaning of the U.S. Private
Securities Litigation Reform Act of 1995 and applicable Canadian
securities laws that may not be based on historical fact. When used
herein, the words “plans”, “expect”, “anticipate”, “estimate”,
“may”, “will”, “should”, “intend,” “believe”, and similar
expressions, are intended to identify forward-looking statements.
Forward-looking statements may involve, but are not limited to,
statements regarding that the safety and efficacy of the Reducer,
the growing incidence of refractory angina, the growing
cardiovascular marketplace, mailing and availability of the
supplement to subscribers, audience size of such subscribers, the
effectiveness of the Reducer and timing of the improved blood
flow, the percentage of patients treated with Reducer
that feel better and experience less chest pain and the ability of
the special supplement to help educate many in Germany on how the
Reducer may offer a medical solution for those suffering from
angina. Forward-looking statements are based on estimates and
assumptions made by the Company in light of its experience and its
perception of historical trends, current conditions and expected
future developments, as well as other factors that the Company
believes are appropriate in the circumstances. Many factors could
cause the Company’s actual results, performance or achievements to
differ materially from those expressed or implied by the
forward-looking statements, including those described in the “Risk
Factors” section of the Company’s Annual Report on Form 20-F and in
the Management’s Discussion and Analysis for the three months ended
March 31, 2020 (copies of which may be obtained at www.sedar.com or
www.sec.gov). These factors should be considered carefully, and
readers should not place undue reliance on the Company’s
forward-looking statements. The Company has no intention and
undertakes no obligation to update or revise any forward-looking
statements, whether as a result of new information, future events
or otherwise.
Media:Sean LeousWestwicke/ICRPhone:
+1.646.866.4012Sean.Leous@icrinc.com
Neovasc (NASDAQ:NVCN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Neovasc (NASDAQ:NVCN)
Historical Stock Chart
From Apr 2023 to Apr 2024